|
|
Post by sportsrancho on Oct 17, 2018 9:44:48 GMT -5
I hear yeah, it was dead to me too, but now it’s on Mike’s checklist so it can’t be. IMO:-) |
|
|
|
Post by mike0475 on Oct 17, 2018 10:17:34 GMT -5
Why did Mike say at SH dinner " you tell me " when asked about RLS?
|
|
|
|
Post by mannmade on Oct 17, 2018 10:22:02 GMT -5
Likely at time he had not heard much from them. But things can change overnight. And oddly enough after he mentioned them on his last cc after a long silence on the subject they raised $7.5m. So you can make your own opinion as to what this means. Imo I think they are a viable partner for Mannkind/TS.
|
|
|
|
Post by uvula on Oct 17, 2018 10:57:43 GMT -5
When we first started talking about RLS it seemed like our only hope of survival. Now we have so much more going for us that RLS doesn't really matter either way.
|
|
|
|
Post by akemp3000 on Oct 17, 2018 11:21:12 GMT -5
My first thought regarding RLS always goes back to Andrea Leone-Bay who left Mannkind, at least technically, to become the Chief Scientific Officer at RLS. Andrea Leone-Bay holds a PhD in Organic Chemistry and has worked in the pharmaceutical industry for over 25 years. She has published 45 manuscripts in peer-reviewed journals and is an inventor on 87 issued US patents. She had to know everything about Mannkind when she was there but chose to join RLS for a reason. I remain anxious to finally learn what that reason was. IMO it relates to one of Al Mann's passions other than diabetes which was pain management or ultra-rapid relief for migraines which plagued his wife. If the cannabis connection with T/S is life changing for migraines and cancer patients, it would be huge and would explain why she left. I remain hopeful RLS will suddenly emerge with a major announcement but like uvula am thinking MNKD is no longer dependent on it.
|
|
|
|
Post by prcgorman2 on Oct 18, 2018 6:16:52 GMT -5
I remembered that Andrea Leone-Bay had gone to RLS but hadn't remembered her name. I had always thought that was significant too, but at the time she left Mannkind and joined RLS I was half-inclined to believe the foo about jumping from a sinking ship. I should have had more faith in her integrity.
And thank you for reminding me about migraine treatment. I've never had a migraine, but my oldest daughter has had a few and I had a former boss who has had to be hospitalized several times because of the severity of his headaches. He's not a wimp so I've always assumed his suffering was real and intense.
He's said that the treatment in the hospital involves an injection (or maybe an IV drip) of some drug or another. You remind me that a Cricket with an inhalable version of that kind of drug would be extremely valuable to migraine sufferers for pain management. Ultra-rapid relief from crippling pain where and when needed would be a blessing.
|
|
|
|
Post by mnholdem on Oct 18, 2018 8:15:48 GMT -5
MannKind has a patent on a Technosphere sumatriptan, an API commonly used for migraines. Pre-clinical studies showed that Sumatriptan-TS would go to work in ~5 minutes, while the widely-prescribed Imitrex (Sumatriptan - GSK) can take over an hour to relieve migraine pain.
|
|
|
|
Post by babaoriley on Oct 18, 2018 12:45:14 GMT -5
I heard a rumor that Andrea left in shame as she was carrying Spiro's baby.  |
|
|
|
Post by mnholdem on Oct 18, 2018 14:00:43 GMT -5
That's chemistry for 'ya!  |
|
|
|
Post by mike0475 on Oct 18, 2018 14:01:20 GMT -5
Baby-here
|
|
|
|
Post by lakers on Oct 18, 2018 15:12:51 GMT -5
MannKind has a patent on a Technosphere sumatriptan, an API commonly used for migraines. Pre-clinical studies showed that Sumatriptan-TS would go to work in ~5 minutes, while the widely-prescribed Imitrex (Sumatriptan - GSK) can take over an hour to relieve migraine pain. mnholdem said: www.google.com/patents/US8785396 - 13. A method of treating a migraine comprising: providing a patient with migraine symptoms an inhaler comprising the pharmaceutical composition of claim 1 in a dry powder form comprising bis-3,6[(N-fumaryl-4-aminobutyl)]-2,5-diketopiperazine, the aliphatic amino acid and 1-50 mg of sumatriptan or rizatriptan; wherein the aliphatic amino acid is L-leucine and wherein a therapeutically effective amount of said dry powder composition is administered to said patient by oral inhalation. The branded version of this drug is call Imitrex, and is manufactured and distributed by GlaxoSmithKline. The generic version is manufactured by Suntory Pharmaceuticals. Here is a link to their webpage for their sumatriptan: www.sumainject.com/aspx/HowToUse.aspxRead more: mnkd.proboards.com/thread/3590/technosphere-migraine-connection-raymond-urbanski#ixzz5UJcQwjJkExpress Scripts Covers Amgen and Lilly, but Snubs Teva's New Migraine Drug www.biospace.com/article/express-scripts-covers-amgen-and-lilly-but-snubs-teva-s-new-migraine-drug/Published: Oct 17, 2018 In its analysis, Reuters said Amgen’s Aimovig is a preferred migraine treatment. However, before a patient can be prescribed the drug, he or she must first try two older preventative treatments, according to the article |
|
|
|
Post by lakers on Oct 20, 2018 12:00:20 GMT -5
Compounds with pre-clinical work done, ready for immediate partnership.
EpiHale: with Mylan, TEVA
Palonosetron: CINV with GSK (Flolan)
Aerodynamic, and temperature stability are done:
Sumatriptan: Migraine with GSK (Imitrex)
Tobra-T: CF with Novartis (TOBI® Podhaler® (Tobramycin Inhalation Powder) ), Chiesi USA (BETHKIS® (Tobramycin Inhalation Solution) indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa), GSK
A second TS partnership is needed to sustain Pps above $3 to grease the skid for $2.38 note conversion in the next few months.
Three possible partnerships with GSK. James, BoD, was GSK CMO.
Humira-T seems the next great candidate for AbbVie. HUMIRA is a $22 B blockbuster in 2018. This could sustain Pps well over $3 * 10X.
|
|
|
|
Post by jlaw277 on Oct 21, 2018 9:13:31 GMT -5
Compounds with pre-clinical work done, ready for immediate partnership. EpiHale: with Mylan, TEVA Palonosetron: CINV with GSK (Flolan) Aerodynamic, and temperature stability are done: Sumatriptan: Migraine with GSK (Imitrex) Tobra-T: CF with Novartis (TOBI® Podhaler® (Tobramycin Inhalation Powder) ), Chiesi USA (BETHKIS® (Tobramycin Inhalation Solution) indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa), GSK A second TS partnership is needed to sustain Pps above $3 to grease the skid for $2.38 note conversion in the next few months. Three possible partnerships with GSK. James, BoD, was GSK CMO. Humira-T seems the next great candidate for AbbVie. HUMIRA is a $22 B blockbuster in 2018. This could sustain Pps well over $3 * 10X. It looks like a deal on Tobramycin would have to be with Mylan due to the recent transaction: www.fiercepharma.com/pharma/mylan-reveals-its-mystery-buy-and-it-s-novartis-tobi-cystic-fibrosis-productsUnless, revamping the delivery system of the tobramycin would constitute a new form of the drug that Novartis could then market. Castagna has stated several times that tobramycin was a likely next step, it being in "Bucket 1." As of a few years ago, tobramycin had US sales of around $350 million. I wonder if the next development won't be a quick follow on deal with UTHR seeing as they are already partners and the deal terms have been predetermined. Clearly, something demanded the timely/immediate delivery of $10 million. See quotation fro press release: "The parties also entered into a research agreement for the conduct of research by MannKind on behalf of United Therapeutics for products outside the scope of the licensing and collaboration agreement. MannKind will receive an immediate payment of $10 million in consideration for its performance under the research agreement." |
|
